5 Stocks Underperforming Today In The Health Services Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 15 points (0.1%) at 16,035 as of Monday, Dec. 9, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,480 issues advancing vs. 1,397 declining with 175 unchanged.

The Health Services industry currently sits up 0.1% versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Centene Corporation ( CNC), up 2.7%. Top gainers within the industry include Given Imaging ( GIVN), up 25.8%, DaVita HealthCare Partners ( DVA), up 4.3%, Parexel International Corporation ( PRXL), up 4.2%, Grifols ( GRFS), up 0.9% and Humana ( HUM), up 0.7%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Catamaran ( CTRX) is one of the companies pushing the Health Services industry lower today. As of noon trading, Catamaran is down $0.64 (-1.4%) to $44.35 on light volume. Thus far, 315,831 shares of Catamaran exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $44.35-$45.16 after having opened the day at $45.03 as compared to the previous trading day's close of $44.99.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $9.2 billion and is part of the health care sector. The company has a P/E ratio of 39.4, above the S&P 500 P/E ratio of 17.7. Shares are down 5.4% year to date as of the close of trading on Friday. Currently there are 11 analysts that rate Catamaran a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, impressive record of earnings per share growth and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Edwards Life ( EW) is down $3.72 (-5.6%) to $62.57 on heavy volume. Thus far, 3.2 million shares of Edwards Life exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $61.91-$64.33 after having opened the day at $62.57 as compared to the previous trading day's close of $66.29.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.1 billion and is part of the health care sector. The company has a P/E ratio of 18.5, above the S&P 500 P/E ratio of 17.7. Shares are down 27.7% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Edwards Life a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Edwards Life Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, St Jude Medical ( STJ) is down $0.35 (-0.6%) to $59.40 on light volume. Thus far, 606,645 shares of St Jude Medical exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $59.32-$59.96 after having opened the day at $59.72 as compared to the previous trading day's close of $59.75.

St. Jude Medical, Inc. develops, manufactures, and distributes cardiovascular and implantable neurostimulation medical devices worldwide. It operates in two divisions, Cardiovascular and Ablation Technologies, and Implantable Electronic Systems. St Jude Medical has a market cap of $16.9 billion and is part of the health care sector. The company has a P/E ratio of 23.5, above the S&P 500 P/E ratio of 17.7. Shares are up 60.7% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate St Jude Medical a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates St Jude Medical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, increase in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full St Jude Medical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Boston Scientific ( BSX) is down $0.10 (-0.8%) to $11.75 on light volume. Thus far, 4.1 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 13.1 million shares. The stock has ranged in price between $11.62-$11.89 after having opened the day at $11.75 as compared to the previous trading day's close of $11.85.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Boston Scientific has a market cap of $15.1 billion and is part of the health care sector. Shares are up 97.9% year to date as of the close of trading on Friday. Currently there are 4 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 16 rate it a hold.

TheStreet Ratings rates Boston Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, compelling growth in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Boston Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Intuitive Surgical ( ISRG) is down $2.69 (-0.7%) to $374.69 on light volume. Thus far, 131,846 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 496,900 shares. The stock has ranged in price between $372.50-$377.05 after having opened the day at $376.39 as compared to the previous trading day's close of $377.38.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $14.0 billion and is part of the health care sector. The company has a P/E ratio of 22.0, above the S&P 500 P/E ratio of 17.7. Shares are down 25.0% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Intuitive Surgical a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full Intuitive Surgical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

McDonald's Limited Risk Is Appealing to Conservative Investors

McDonald's Limited Risk Is Appealing to Conservative Investors

Dow Rises as Wall Street Likes Progress in U.S.-China Trade Talks

Dow Rises as Wall Street Likes Progress in U.S.-China Trade Talks

Is McDonald's Stock Worth It?

Is McDonald's Stock Worth It?

Expect Less M&A in 2019 as Big Year Comes to a Close

Expect Less M&A in 2019 as Big Year Comes to a Close

JPMorgan CEO's `Golden Age of Banking' Is Proving Short-Lived

JPMorgan CEO's `Golden Age of Banking' Is Proving Short-Lived